Jyong Biotech Ltd. Ordinary Shares(MENS)Earnings, Financials & Key Ratios
MENS•NASDAQ
$2.15
$160M mkt cap·Price updated May 6, 2026
AboutJyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stagesShow more
- Revenue$0
- EBITDA-$2M+27.5%
- Net Income-$3M+31.4%
- EPS (Diluted)-0.04+31.4%
- Interest Coverage-1.99+46.2%
MENS Key Insights
Jyong Biotech Ltd. Ordinary Shares (MENS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MENS Price & Volume
Jyong Biotech Ltd. Ordinary Shares (MENS) stock price & volume — 10-year historical chart
Loading chart...
MENS Growth Metrics
Jyong Biotech Ltd. Ordinary Shares (MENS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-40.87%
5 Years-40.87%
3 Years-
Last Year-
MENS Peer Comparison
Jyong Biotech Ltd. Ordinary Shares (MENS) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AEYE | 95.09M | 7.66 | -30.64 | 14.52% | -7.63% | -47.8% | 0.15 | |
 NUVB | 1.75B | 5.04 | -8.40 | 6.99% | -102.06% | -44.1% | 0.03 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 NVAX | 1.53B | 9.36 | 3.69 | 64.69% | -14.73% | |||
 OCGN | 492.54M | 1.46 | -6.33 | 8.83% | -15.37% | -26.26% | ||
 ICLR | 9.48B | 124.13 | 13.03 | 1.99% | 7.4% | 6.32% | 0.38 | |
 CRL | 8.97B | 181.73 | -62.45 | -0.85% | -3.59% | -4.34% | 0.95 | |
 MEDP | 12.19B | 426.79 | 27.93 | 19.97% | 17.19% | 120.89% | 0.55 |
Compare MENS vs Peers
Jyong Biotech Ltd. Ordinary Shares (MENS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MENS Income Statement
Jyong Biotech Ltd. Ordinary Shares (MENS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 0 | 121K | 122K | 127K | 120K |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0▲ 0% | -121K▲ 0% | -122K▼ 0.8% | -127K▼ 4.1% | -120K▲ 5.5% |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | -0.83% | -4.1% | 5.51% |
| Operating Expenses | 2.45M | 2.4M | 2.83M | 2.8M | 2.06M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 931K | 845K | 1.54M | 1.73M | 1.13M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 1.51M | 1.56M | 1.29M | 1.07M | 927K |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.45M▲ 0% | -2.4M▲ 1.7% | -2.83M▼ 17.7% | -2.8M▲ 1.1% | -2.06M▲ 26.5% |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | 1.72% | -17.68% | 1.13% | 26.49% |
| EBITDA | -2.34M | -2.28M | -2.71M | -2.67M | -1.94M |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | - | 2.31% | -18.58% | 1.33% | 27.49% |
| D&A (Non-Cash Add-back) | 110K | 122K | 123K | 127K | 120K |
| EBIT | -2.45M | -3.36M | -5.87M | -3.64M | -1.98M |
| Net Interest Income | -832K | -829K | -760K | -701K | -1.03M |
| Interest Income | 0 | 6K | 5K | 56K | 7K |
| Interest Expense | 832K | 835K | 765K | 757K | 1.03M |
| Other Income/Expense | 530K | -1.79M | -3.8M | -1.6M | -963K |
| Pretax Income | -1.92M▲ 0% | -4.2M▼ 119.1% | -6.63M▼ 57.9% | -4.4M▲ 33.6% | -3.02M▲ 31.4% |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.92M▲ 0% | -4.2M▼ 119.1% | -6.63M▼ 57.9% | -4.4M▲ 33.6% | -3.02M▲ 31.4% |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | - | -119.1% | -57.93% | 33.63% | 31.39% |
| Net Income (Continuing) | -1.92M | -4.2M | -6.63M | -4.4M | -3.02M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.03▲ 0% | -0.06▼ 106.0% | -0.09▼ 58.0% | -0.06▲ 33.6% | -0.04▲ 31.4% |
| EPS Growth % | - | -105.97% | -57.97% | 33.6% | 31.43% |
| EPS (Basic) | -0.03 | -0.06 | -0.09 | -0.06 | -0.04 |
| Diluted Shares Outstanding | 71.57M | 76.03M | 76.03M | 76.03M | 76.03M |
| Basic Shares Outstanding | 71.57M | 76.03M | 76.03M | 76.03M | 76.03M |
| Dividend Payout Ratio | - | - | - | - | - |
MENS Balance Sheet
Jyong Biotech Ltd. Ordinary Shares (MENS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|
| Total Current Assets | 6.22M | 2.65M | 2.46M | 1.84M | 206K |
| Cash & Short-Term Investments | 4.22M | 2.38M | 812K | 177K | 98K |
| Cash Only | 3.56M | 551K | 718K | 177K | 98K |
| Short-Term Investments | 664K | 1.83M | 94K | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 1.6M | 263K | 1.65M | 1.66M | 108K |
| Total Non-Current Assets | 6.62M | 6.78M | 6.28M | 6.41M | 6.16M |
| Property, Plant & Equipment | 6.61M | 6.78M | 6M | 3.54M | 3.19M |
| Fixed Asset Turnover | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 10K | 8K | 283K | 2.87M | 2.97M |
| Total Assets | 12.84M▲ 0% | 9.43M▼ 26.6% | 8.74M▼ 7.3% | 8.25M▼ 5.7% | 6.37M▼ 22.8% |
| Asset Turnover | - | - | - | - | - |
| Asset Growth % | - | -26.56% | -7.28% | -5.68% | -22.82% |
| Total Current Liabilities | 5.78M | 6.29M | 12.91M | 14.26M | 12.13M |
| Accounts Payable | 25K | 46K | 4K | 2K | 3K |
| Days Payables Outstanding | - | 138.76 | 11.97 | 5.75 | 9.13 |
| Short-Term Debt | 4.83M | 4.93M | 7.65M | 7.97M | 7.28M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 151K | 23K | 4.22M | 4.99M | 3.33M |
| Current Ratio | 1.08x | 0.42x | 0.19x | 0.13x | 0.02x |
| Quick Ratio | 1.08x | 0.42x | 0.19x | 0.13x | 0.02x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 26.27M | 26.46M | 25.47M | 28.06M | 30.76M |
| Long-Term Debt | 8.29M | 6.26M | 6.32M | 8.52M | 10.68M |
| Capital Lease Obligations | 359K | 346K | 115K | 69K | 16K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 17.62M | 19.86M | 19.04M | 19.47M | 20.06M |
| Total Liabilities | 32.05M | 32.76M | 38.38M | 42.32M | 42.88M |
| Total Debt | 13.6M | 11.79M | 14.25M | 16.69M | 18.14M |
| Net Debt | 10.04M | 11.24M | 13.53M | 16.51M | 18.04M |
| Debt / Equity | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | -2.94x | -2.88x | -3.70x | -3.69x | -1.99x |
| Total Equity | -19.2M▲ 0% | -23.32M▼ 21.5% | -29.63M▼ 27.0% | -34.07M▼ 15.0% | -36.52M▼ 7.2% |
| Equity Growth % | - | -21.46% | -27.04% | -14.99% | -7.18% |
| Book Value per Share | -0.27 | -0.31 | -0.39 | -0.45 | -0.48 |
| Total Shareholders' Equity | -19.2M | -23.32M | -29.63M | -34.07M | -36.52M |
| Common Stock | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | -14.83M | -19.03M | -25.66M | -30.06M | -33.08M |
| Treasury Stock | -16.37M | -16.37M | -16.37M | -16.37M | -16.37M |
| Accumulated OCI | 189K | 266K | 590K | 548K | 1.12M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
MENS Cash Flow Statement
Jyong Biotech Ltd. Ordinary Shares (MENS) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|
| Cash from Operations | -1.09M | -1.98M | -2.97M | -2.6M | -3.62M |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | - | -82.52% | -49.75% | 12.45% | -39.33% |
| Net Income | -1.92M | -4.2M | -6.63M | -4.4M | -3.02M |
| Depreciation & Amortization | 110K | 122K | 123K | 127K | 120K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 694K | 849K | 599K | 554K | 761K |
| Working Capital Changes | 25K | 1.24M | 2.94M | 1.12M | -1.49M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 21K | -28K | -2K | 1K |
| Cash from Investing | 731K | -1.31M | 1.39M | 95K | 0 |
| Capital Expenditures | -88K | -137K | -246K | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 819K | 0 | 0 | 0 | 0 |
| Cash from Financing | 4.91M | -1.38M | 3.33M | 2.03M | 1.99M |
| Debt Issued (Net) | 2.39M | -1.35M | 3.61M | 2.47M | 2.2M |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 2.52M | -35K | -276K | -445K | -213K |
| Net Change in Cash | 5.16M▲ 0% | -4.61M▼ 189.3% | 1.72M▲ 137.4% | -532K▼ 130.9% | -1.64M▼ 208.5% |
| Free Cash Flow | -1.18M▲ 0% | -2.12M▼ 80.5% | -3.22M▼ 51.7% | -2.6M▲ 19.1% | -3.62M▼ 39.3% |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | - | -80.51% | -51.67% | 19.15% | -39.33% |
| FCF per Share | -0.02 | -0.03 | -0.04 | -0.03 | -0.05 |
| FCF Conversion (FCF/Net Income) | 0.57x | 0.47x | 0.45x | 0.59x | 1.20x |
| Interest Paid | 88K | 106K | 162K | 104K | 223K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
MENS Key Ratios
Jyong Biotech Ltd. Ordinary Shares (MENS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Interest Coverage | -2.94x | -2.88x | -3.70x | -3.69x | -1.99x |
| FCF Conversion | 0.57x | 0.47x | 0.45x | 0.59x | 1.20x |
MENS Frequently Asked Questions
Jyong Biotech Ltd. Ordinary Shares (MENS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Jyong Biotech Ltd. Ordinary Shares (MENS) grew revenue by 0.0% over the past year. Growth has been modest.
Jyong Biotech Ltd. Ordinary Shares (MENS) reported a net loss of $0.0M for fiscal year 2024.
Dividend & Returns
Jyong Biotech Ltd. Ordinary Shares (MENS) had negative free cash flow of $0.0M in fiscal year 2024, likely due to heavy capital investments.
Explore More MENS
Jyong Biotech Ltd. Ordinary Shares (MENS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates